Renal-Cell Cancer

Metastatic renal cell cancer

Targeted therapy is the treatment of choice in patients with metastatic renal cell cancer (mRCC) at most institutions although a combination of cytokine therapy and targeted therapy still is being investigated. Morphological size-based criteria (RECIST) has failed in monitoring the effect of targeted therapy in patients with mRCC, as successful therapy often does not result in a decrease in tum...

Renal cell cancer without a renal primary

Renal cell carcinoma has been increasing in incidence over the past two decades. Men are affected more than women and metastatic disease at presentation occurs in up to one third of patients. Metastasis can occur to virtually any organ, and involvement of multiple organs is not uncommon. To date, no reports have been found of metastatic disease without a renal primary. We present a case of rena...

Immunotherapy for renal cell cancer.

In the West, renal cell cancer accounts for 2% of all and 1993.6 This failure of chemotherapy could be explained by the high levels of expression of the cancers. Over 4000 new cases are currently reported multi-drug resistance gene in renal tumours.7 Two annually in the UK1 and a worldwide mortality in highly homologous genes, MDR1 and MDR2, located excess of 100 000 deaths is predicted in the ...

Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells

Renal cell carcinoma (RCC) is a common form of urologic tumor that originates from the highly heterogeneous epithelium of renal tubules. Over the last decade, targeting therapies to renal cancer cells have transformed clinical care for RCC. Recently, it was proposed that renal cancer stem cells (CSCs) isolated from renal carcinomas were responsible for driving tumor growth and resistance to con...

Sarcomatoid Transrormation of Chromophobe Renal Cell Carcinoma